The epilepsy-movement disorder phenotypic spectrum and phenytoin-induced dyskinesia associated with GABRB3 pathogenic variants

Epileptic Disord. 2021 Dec 1;23(6):947-950. doi: 10.1684/epd.2021.1343.

Authors

Amaar Marefi¹, Myriam Srour²

Affiliations

¹ Division of Pediatric Neurology, Departments of Pediatrics and Neurology & Neurosurgery, McGill University, Montreal, Quebec, Canada.
² Division of Pediatric Neurology, Departments of Pediatrics and Neurology & Neurosurgery, McGill University, Montreal, Quebec, Canada, McGill University Health Center Research Institute, Montreal, Quebec, Canada.

PMID: 34668866
DOI: 10.1684/epd.2021.1343

No abstract available

MeSH terms

Dyskinesia, Drug-Induced / epidemiology
Dyskinesia, Drug-Induced / genetics
Epilepsy* / drug therapy
Epilepsy* / genetics
Humans
Movement Disorders* / genetics
Phenytoin* / adverse effects
Receptors, GABA-A / genetics

Substances

GABRB3 protein, human
Receptors, GABA-A
Phenytoin